ProPep Surgical® Secures $1.25 Million in Series A Financing

Share Article

The ProPep Nerve Monitoring System is the first, real-time nerve monitoring system specifically designed for use during robotic surgery.

Real-time Nerve Identification for Robotic Surgery

ProPep Surgical, LLC. (, a privately-held, Austin-based medical device company developing intraoperative nerve monitoring technologies for minimally invasive, robotic-assisted surgery, announced today it has secured $1.25 million in Series A financing from Stella Maris Partners. The Company will use the funds to scale up the US sales and distribution of its ProPep Nerve Monitoring System™ and to support initial studies exploring the benefits of real-time, intraoperative nerve monitoring in robotic-assisted hysterectomy and colorectal surgery.

“Stella Maris Partners (SMP) is very proud to participate in this round of investment,” said Armando Badillo, SMP General Partner. “We believe ProPep Surgical’s proprietary method of utilizing clinically proven technology to deliver the benefits of real time nerve monitoring to robotic-assisted surgical procedures will provide surgeons with better information which will improve intra-operative decision making and ultimately, improve patient outcomes.”

ProPep’s initial product offering, the ProPep Nerve Monitoring System, is currently FDA-cleared and CE-marked for use during robotic-assisted prostatectomy surgery. The System is designed to help surgeons identify the location of and monitor the integrity of otherwise invisible pelvic nerves in real time throughout the surgical procedure. By allowing the surgeon to identify the location of the nerves at the beginning of the surgery, verify the location and function of the nerves throughout the surgery, and validate the preservation of the nerves at the completion of the operation, the ProPep Nerve Monitoring System provides surgeons instant and continuous, real time information on nerve location and function. This information can potentially help the surgeon reduce the incidence of inadvertent damage to these critical nerves and in so doing, potentially reduce the common side effects (e.g., urinary incontinence) often attributed to this nerve damage.

About Stella Maris Partners
Stella Maris Partners was founded in 2012, as a global private equity firm investing in Health, Technology, and Education companies who align with their ethical core values. We help and urge our partners to bring businesses to the next level of performance.

About ProPep Surgical, LLC
Established in 2010, ProPep Surgical is a privately-held, Austin-based medical device company developing real-time, intraoperative nerve monitoring technologies for minimally invasive, robotic-assisted surgery. Real time identification of these otherwise invisible nerves will allow the surgeons to make a more informed decision about which tissue to selectively preserve or remove during robotic-assisted surgery and in so doing potentially reduce the common side effects typically attributed to inadvertent nerve damage during these surgical procedures. For more information, visit

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Jim Schneider
Follow us on
Visit website